MAPT and Alzheimer disease: The International Working Group (IWG) and the US National Institute on Aging–Alzheimer’s Association in 2014 defined new criteria for AD diagnosis [7] based on recent advances in neuroimaging and biomarkers including: increased tracer retention on amyloid positron emission tomography (PET) or decreased Aβ 1–42 together with increased total-tau (T-tau) or phosphorylated (P-tau) in cerebrospinal fluid (CSF).